Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.
Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.
Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.
Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.
Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.
Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.
Emergent BioSolutions (NYSE:EBS) has secured a significant $51.9 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for its CNJ-016® (VIGIV) treatment. The contract is part of the U.S. government's smallpox preparedness strategy, extending an existing 10-year agreement for additional doses of VIGIV, which treats complications from smallpox vaccination.
The announcement follows Emergent's recent BAT® (Botulism Antitoxin Heptavalent) contract amendment with ASPR. VIGIV is a 5% Liquid Immune Globulin treatment indicated for various vaccinia vaccination complications, including eczema vaccinatum and progressive vaccinia, though not for postvaccinial encephalitis.
Emergent BioSolutions (NYSE:EBS) has expanded its NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, complementing its existing NARCAN® 4 mg nasal spray offering. The expansion, effective July 1, 2025, follows Emergent's acquisition of KLOXXADO's exclusive commercial rights in the U.S. and Canada in January 2025.
The platform serves qualified direct purchasers including emergency services, law enforcement, schools, and community-based programs. The company is also introducing Convenience Kits featuring CPR masks and nitrile gloves. This expansion comes as CDC data shows a 27% decrease in drug overdose deaths in 2024, though recent data indicates a slight uptick of 1,400 deaths between January 2024 and January 2025.
Emergent BioSolutions (NYSE: EBS) has announced its participation in multiple upcoming investor conferences in May and June 2025. The company's executive management team will attend:
- RBC Global Healthcare Conference in New York (May 20) featuring a fireside chat at 3:35 pm ET
- Goldman Sachs Leveraged Finance Conference in Dana Point, California (May 29)
- Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference (May 29)
- Jefferies Global Healthcare Conference in New York (June 5) with a presentation at 1:25 pm ET
Virtual attendance options are available for select events, and presentation replays will be accessible through Emergent's website investor page.
Emergent BioSolutions (NYSE: EBS) has secured a three-year agreement worth approximately $65 million with the Ontario Ministry of Health to supply NARCAN® Nasal Spray through the Ontario Naloxone Program (ONP). The agreement aims to distribute the opioid overdose reversal medication across Ontario through various community-based organizations.
NARCAN® is the only 4 mg intranasal naloxone spray in Canada with a 48-month shelf life. Recent data shows a 30% decrease in overdose deaths in Ontario from January to March 2025 compared to the previous year, though the province still recorded 653 suspect drug-related fatalities during this period. The company also recently received Health Canada's approval for KLOXXADO® Nasal Spray 8 mg, demonstrating its continued commitment to addressing the opioid crisis.
Emergent BioSolutions (NYSE: EBS) has scheduled its first quarter 2025 financial results conference call for May 7, 2025, at 5:00 pm eastern time. The company will provide investors and stakeholders access to the conference call through multiple channels:
- Live webcast access
- Telephone participation (requires advance registration)
- Replay availability on the company's Investors webpage
Registered telephone participants will receive confirmation emails with dial-in details, including a unique passcode and registrant ID for call access.